Published on
November 24, 2025
- 18:25 GMT
ACA Pharma Announces Major Expansion of RYANODEX® Territory Outside the United States
Expanded collaboration significantly broadens ACA Pharma’s ex-U.S. commercialization footprint for RYANODEX® NEW YORK, NY, UNITED STATES, November 24, 2025 /EINPresswire.com/ -- ACA Pharma today announced a significant expansion of their exclusive territory for RYANODEX® (dantrolene sodium) outside the United States. Ryanodex® is indicated for the treatment of malignant hyperthermia and for the prevention of malignant hyperthermia in patients at high risk. Eagle Pharmaceuticals, Inc. is the developer …
Distribution channels:
Business & Economy, Companies
...